EUVIMEDEUVIMED entdecken
Crossref

Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy

Dongyoon Kim, Jaehyun Choi, Dongun Jin, Enzhen Xu, Jaiwoo Lee, Junho Byun, Yu-Kyoung Oh

Journal of Controlled Release · 2025-03 · 379 · 537-548

DOI: 10.1016/j.jconrel.2025.01.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Dongyoon Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Nanoparticles, Dendritic Cells, Immunotherapy, Antigens, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Korea Evaluation Institute of Industrial Technology, Korea Ministry of Trade Industry and Energy, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-surgical tumor recurrence poses a major challenge in cancer treatment due to residual tumor cells and surgery-induced immunosuppression. Here, we developed hybrid nanoparticles, termed T-DCNPs, designed to promote antigen-specific activation of cytotoxic CD8+ T cells while concurrently inhibiting immunosuppressive pathways within the tumor microenvironment. T-DCNPs were formulated by co-extruding lipid nanoparticles containing a transforming growth factor β inhibitor with dendritic cells that were pre-treated with autologous neoantigens derived from surgically excised tumors. By using whole tumor antigens rather than specific peptides, T-DCNPs effectively overcame tumor heterogeneity and elicited a robust, targeted immune response. In vitro studies showed that T-DCNPs enhanced CD8+ T cell proliferation and reduced programmed death-1 (PD-1) expression, leading to increased antitumor cytotoxicity. In vivo experiments, involving intratumoral injections of T-DCNPs in distant tumor and post-surgical melanoma models, demonstrated a significant reduction in distant tumor growth, decreased recurrence rates, and extended survival compared to control groups. Flow cytometry and immunohistochemistry analyses further confirmed the enhanced infiltration of activated CD8+ T cells and a marked reduction in immunosuppressive markers, including PD-1 and Foxp3, within the treated tumors. These results suggest that T-DCNPs, through the dual mechanisms of tumor antigen-specific T cell activation and immune modulation, offer a promising strategy to prevent tumor recurrence following surgery and could potentially improve the efficacy of postoperative cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesDendritic CellsImmunotherapyAntigens, NeoplasmAnimalsMice, Inbred C57BLCD8-Positive T-LymphocytesFemaleCell Line, TumorProgrammed Cell Death 1 ReceptorHumansMiceLipidsCell MembraneTransforming Growth Factor beta

Stichwörter der Autor:innen

Dendritic cell membranesHybrid lipid nanoparticlePost-surgical tumor recurrence,tumor antigen-specific immunotherapyTumor antigen priming

Substanzen

Antigens, NeoplasmProgrammed Cell Death 1 ReceptorLipidsTransforming Growth Factor beta

Autor:innen und Institutionen

  • College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
  • College of Pharmacy, Korea University, Sejong 30019, Republic of Korea. Electronic address: ljw1112@korea.ac.kr.
  • College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea. Electronic address: junho_byun@sookmyung.ac.kr.
  • College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Electronic address: ohyk@snu.ac.kr.

Förderung

  • Korea Evaluation Institute of Industrial Technology
  • Korea Ministry of Trade Industry and Energy
  • National Research Foundation of Korea
  • Korea Ministry of Science and ICT

Zitieren

APA

Kim, D., Choi, J., Jin, D., Xu, E., Lee, J., Byun, J., & Oh, Y. K. (2025). Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy. Journal of Controlled Release, 379, 537-548. https://doi.org/10.1016/j.jconrel.2025.01.027

Vancouver

Kim D, Choi J, Jin D, Xu E, Lee J, Byun J, et al. Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy. Journal of Controlled Release. 2025;379:537-548. doi:10.1016/j.jconrel.2025.01.027

BibTeX
@article{Kim2025,
  author = {Kim, Dongyoon and Choi, Jaehyun and Jin, Dongun and Xu, Enzhen and Lee, Jaiwoo and Byun, Junho and Oh, Yu-Kyoung},
  title = {Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {379},
  pages = {537--548},
  doi = {10.1016/j.jconrel.2025.01.027}
}
Kostenlos starten →